124 related articles for article (PubMed ID: 17626395)
1. Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics.
Harpole DH
Thorac Surg Clin; 2007 May; 17(2):167-73, viii. PubMed ID: 17626395
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
Nakajima E; Katou H
Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
4. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N
Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056
[TBL] [Abstract][Full Text] [Related]
5. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
6. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Johnson BE; Rabin MS
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
[TBL] [Abstract][Full Text] [Related]
7. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
8. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
9. Resected non-small-cell lung cancer stage I/II: indication for adjuvant/neoadjuvant therapy?
Hoffmann H
Lung Cancer; 2004 Aug; 45 Suppl 2():S91-7. PubMed ID: 15552788
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks.
Sawyer TE; Bonner JA; Gould PM; Foote RL; Deschamps C; Trastek VF; Pairolero PC; Allen MS; Lange CM; Li H
Ann Thorac Surg; 1997 Nov; 64(5):1402-7; discussion 1407-8. PubMed ID: 9386711
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy.
Brahmer JR; Ettinger DS
Respirology; 2007 May; 12(3):320-5. PubMed ID: 17539833
[TBL] [Abstract][Full Text] [Related]
12. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
Petersen RP; Campa MJ; Sperlazza J; Conlon D; Joshi MB; Harpole DH; Patz EF
Cancer; 2006 Dec; 107(12):2866-72. PubMed ID: 17099880
[TBL] [Abstract][Full Text] [Related]
13. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment of early stage non-small-cell lung cancer.
Wada H
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):102-5. PubMed ID: 10442375
[TBL] [Abstract][Full Text] [Related]
15. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
16. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
17. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
19. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
